JP2002522041A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002522041A5 JP2002522041A5 JP2000563766A JP2000563766A JP2002522041A5 JP 2002522041 A5 JP2002522041 A5 JP 2002522041A5 JP 2000563766 A JP2000563766 A JP 2000563766A JP 2000563766 A JP2000563766 A JP 2000563766A JP 2002522041 A5 JP2002522041 A5 JP 2002522041A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- amino acid
- nucleic acid
- polynucleotide
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 description 147
- 229920001184 polypeptide Polymers 0.000 description 145
- 102000004196 processed proteins & peptides Human genes 0.000 description 145
- 102000039446 nucleic acids Human genes 0.000 description 88
- 108020004707 nucleic acids Proteins 0.000 description 88
- 150000007523 nucleic acids Chemical class 0.000 description 87
- 125000003275 alpha amino acid group Chemical group 0.000 description 74
- 108091033319 polynucleotide Proteins 0.000 description 71
- 102000040430 polynucleotide Human genes 0.000 description 71
- 239000002157 polynucleotide Substances 0.000 description 71
- 239000002773 nucleotide Substances 0.000 description 63
- 125000003729 nucleotide group Chemical group 0.000 description 63
- 239000002299 complementary DNA Substances 0.000 description 43
- 210000004027 cell Anatomy 0.000 description 23
- 239000008194 pharmaceutical composition Substances 0.000 description 21
- 238000000034 method Methods 0.000 description 18
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 17
- 239000005557 antagonist Substances 0.000 description 17
- 229930182817 methionine Natural products 0.000 description 14
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 14
- 125000000539 amino acid group Chemical group 0.000 description 11
- 238000004519 manufacturing process Methods 0.000 description 11
- 150000001413 amino acids Chemical class 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 238000009396 hybridization Methods 0.000 description 8
- 230000001575 pathological effect Effects 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 6
- -1 Amino Chemical group 0.000 description 5
- 230000000295 complement effect Effects 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 4
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 208000036142 Viral infection Diseases 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- 241000972773 Aulopiformes Species 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 229960000633 dextran sulfate Drugs 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000010188 recombinant method Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 235000019515 salmon Nutrition 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 206010063094 Cerebral malaria Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 206010020460 Human T-cell lymphotropic virus type I infection Diseases 0.000 description 1
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 1
- 241000714259 Human T-lymphotropic virus 2 Species 0.000 description 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 108010076039 Polyproteins Proteins 0.000 description 1
- 241000702263 Reovirus sp. Species 0.000 description 1
- 241000555745 Sciuridae Species 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/131,237 US6599719B2 (en) | 1994-11-07 | 1998-08-07 | Nucleic acid molecules encoding tumor necrosis factor-gamma-alpha |
| US09/131,237 | 1998-08-07 | ||
| PCT/US1999/002722 WO2000008139A1 (en) | 1998-08-07 | 1999-02-08 | Tumor necrosis factor-gamma |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002522041A JP2002522041A (ja) | 2002-07-23 |
| JP2002522041A5 true JP2002522041A5 (enExample) | 2006-03-16 |
Family
ID=22448549
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000563766A Pending JP2002522041A (ja) | 1998-08-07 | 1999-02-08 | 腫瘍壊死因子γ |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US6599719B2 (enExample) |
| EP (1) | EP1100886A4 (enExample) |
| JP (1) | JP2002522041A (enExample) |
| KR (1) | KR20010085351A (enExample) |
| CN (1) | CN1322244A (enExample) |
| AU (2) | AU775071B2 (enExample) |
| CA (1) | CA2338186C (enExample) |
| NZ (2) | NZ526411A (enExample) |
| WO (1) | WO2000008139A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7820798B2 (en) * | 1994-11-07 | 2010-10-26 | Human Genome Sciences, Inc. | Tumor necrosis factor-gamma |
| US6599719B2 (en) * | 1994-11-07 | 2003-07-29 | Human Genome Sciences, Inc. | Nucleic acid molecules encoding tumor necrosis factor-gamma-alpha |
| WO1997033904A1 (en) | 1996-03-12 | 1997-09-18 | Human Genome Sciences, Inc. | Death domain containing receptors |
| US6713061B1 (en) | 1996-03-12 | 2004-03-30 | Human Genome Sciences, Inc. | Death domain containing receptors |
| US7357927B2 (en) | 1996-03-12 | 2008-04-15 | Human Genome Sciences, Inc. | Death domain containing receptors |
| EP1992633A1 (en) * | 1997-11-03 | 2008-11-19 | Human Genome Sciences, Inc. | VEGI, an inhibitor of angiogenesis and tumor growth |
| US6627199B1 (en) | 1999-07-09 | 2003-09-30 | Amgen Inc | Isolation, identification and characterization of tmst2, a novel member of the TNF-receptor supergene family |
| WO2001010908A1 (en) * | 1999-08-04 | 2001-02-15 | Amgen Inc. | Ntr3, a member of the tnf-receptor supergene family |
| MXPA02001264A (es) * | 1999-08-04 | 2002-07-22 | Amgen Inc | Fhm, nuevo miembro de la familia de supergenes de ligando de factor de necrosis tumoral. |
| US6346247B1 (en) * | 1999-10-28 | 2002-02-12 | Promega Corporation | Prevention and treatment of autoimmune disease with luminally administered polyclonal antibodies |
| CN1329024A (zh) * | 2000-06-21 | 2002-01-02 | 上海博德基因开发有限公司 | 一种新的多肽——活化gtp酶的蛋白负调控子11.66和编码这种多肽的多核苷酸 |
| AU2001277857A1 (en) * | 2000-07-07 | 2002-01-21 | Human Genome Sciences, Inc. | Tumor necrosis factor-gamma |
| WO2002047540A2 (en) * | 2000-12-15 | 2002-06-20 | The General Hospital Corporation | Methods for inhibiting fibrosis |
| ATE466020T1 (de) | 2001-11-09 | 2010-05-15 | Univ Georgetown | Neue isoform des gefässendothelzell wachstumshemmers (vegi) |
| US7390797B2 (en) | 2002-02-28 | 2008-06-24 | Eisai Co., Ltd. | Fused indazole compounds |
| MXPA05006147A (es) | 2002-12-10 | 2005-08-26 | Schering Plough Ltd | Ligando del activador del receptor de nf-kb de canino, y metodos para preparar y usar el mismo. |
| US20050075543A1 (en) * | 2003-10-03 | 2005-04-07 | Calabrese Charles A. | Method of anonymous medical testing and providing the patient with the test results |
| US20050227920A1 (en) * | 2003-12-11 | 2005-10-13 | Xinli Lin | Methods for production of recombinant vascular endothelial cell growth inhibitor |
| JP2005173484A (ja) * | 2003-12-15 | 2005-06-30 | Canon Inc | 画像形成装置及びプロセスカートリッジ |
| EP2205971A4 (en) * | 2007-10-04 | 2011-03-30 | Bionomics Ltd | ENDOTHEL CELL MARKERS AND USES THEREOF |
| US20110229471A1 (en) | 2008-11-26 | 2011-09-22 | Cedars-Sinai Medical Center | Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease |
| KR20240122922A (ko) | 2013-03-27 | 2024-08-13 | 세다르스-신나이 메디칼 센터 | Tl1a 기능 및 관련된 신호전달 경로의 저해에 의한 섬유증 및 염증의 완화 및 반전 |
| EP3022295A4 (en) | 2013-07-19 | 2017-03-01 | Cedars-Sinai Medical Center | Signature of tl1a (tnfsf15) signaling pathway |
| CN109462996A (zh) | 2016-03-17 | 2019-03-12 | 西达-赛奈医疗中心 | 通过rnaset2诊断炎性肠病的方法 |
| MY191324A (en) | 2016-10-26 | 2022-06-15 | Cedars Sinai Medical Center | Neutralizing anti-tl1a monoclonal antibodies |
| CN119735681A (zh) | 2018-04-25 | 2025-04-01 | 普罗米修斯生物科学公司 | 优化的抗tl1a抗体 |
| TW202600603A (zh) | 2019-10-24 | 2026-01-01 | 美商普羅米修斯生物科學股份有限公司 | 針對類-tnf配體1a (tl1a)之人類化抗體及其用途 |
| CN114632161B (zh) * | 2020-12-16 | 2024-02-06 | 中国人民解放军军事科学院军事医学研究院 | 肿瘤坏死因子-α作为一种核酸基因药物体内递送载体的应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4677063A (en) | 1985-05-02 | 1987-06-30 | Cetus Corporation | Human tumor necrosis factor |
| IL106271A (en) | 1992-09-03 | 2008-03-20 | Yeda Res & Dev | Ligand to TNF 75P receptor and its preparation |
| DE69033710T2 (de) | 1989-10-24 | 2001-06-13 | Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville | Sekretion vom mit Gamma-Interferon Signalpeptid gebundenen humänen Protein |
| WO1991012340A1 (en) * | 1990-02-14 | 1991-08-22 | The Regents Of The University Of Michigan | Methods and products for the synthesis of oligosaccharide structures on glycoproteins, glycolipids, or as free molecules |
| US5464938A (en) | 1990-04-09 | 1995-11-07 | Immunex Corporation | Isolated viral protein TNF antagonists |
| US5476781A (en) * | 1991-02-19 | 1995-12-19 | University Of Florida Research Foundation, Inc. | Entomopoxvirus spheroidin gene sequences |
| CA2114311C (en) | 1991-11-25 | 1996-02-27 | Richard Kian-Hock Wee | Monoclonal wb b-cell line |
| US5573924A (en) | 1992-09-08 | 1996-11-12 | Immunex Corporation | CD27 ligand |
| US5891679A (en) | 1993-02-03 | 1999-04-06 | N.V. Innogenetics S.A. | TNF-alpha muteins and a process for preparing them |
| US5472856A (en) * | 1993-12-21 | 1995-12-05 | Immunobiology Research Institute, Inc. | Recombinant human thymopoietin proteins and uses therefor |
| US6867288B1 (en) * | 1994-10-12 | 2005-03-15 | Genzyme Corporation | Polycystic kidney disease gene |
| US6599719B2 (en) * | 1994-11-07 | 2003-07-29 | Human Genome Sciences, Inc. | Nucleic acid molecules encoding tumor necrosis factor-gamma-alpha |
| JP4046349B2 (ja) | 1994-11-07 | 2008-02-13 | ヒューマン ジノーム サイエンシーズ， インコーポレイテッド | 腫瘍壊死因子−γ |
| WO1996040774A1 (en) * | 1995-06-07 | 1996-12-19 | Biogen, Inc. | Complexes of modified lymphotoxins as pharmaceutical preparations |
| EP1992633A1 (en) * | 1997-11-03 | 2008-11-19 | Human Genome Sciences, Inc. | VEGI, an inhibitor of angiogenesis and tumor growth |
| MXPA02001264A (es) * | 1999-08-04 | 2002-07-22 | Amgen Inc | Fhm, nuevo miembro de la familia de supergenes de ligando de factor de necrosis tumoral. |
-
1998
- 1998-08-07 US US09/131,237 patent/US6599719B2/en not_active Expired - Fee Related
-
1999
- 1999-02-08 KR KR1020017001659A patent/KR20010085351A/ko not_active Ceased
- 1999-02-08 EP EP99905874A patent/EP1100886A4/en not_active Withdrawn
- 1999-02-08 CN CN99811864A patent/CN1322244A/zh active Pending
- 1999-02-08 JP JP2000563766A patent/JP2002522041A/ja active Pending
- 1999-02-08 AU AU25934/99A patent/AU775071B2/en not_active Expired
- 1999-02-08 WO PCT/US1999/002722 patent/WO2000008139A1/en not_active Ceased
- 1999-02-08 NZ NZ526411A patent/NZ526411A/en not_active IP Right Cessation
- 1999-02-08 CA CA2338186A patent/CA2338186C/en not_active Expired - Lifetime
- 1999-02-08 NZ NZ509560A patent/NZ509560A/en not_active IP Right Cessation
-
2004
- 2004-07-29 AU AU2004203451A patent/AU2004203451A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3502102B2 (ja) | 新規蛋白質及びその製造方法 | |
| JP2002516103A5 (enExample) | ||
| HK1040531B (zh) | 制备哺乳动物细胞激动素合成抑制因子的方法 | |
| WO2005072340A2 (en) | Novel polynucleotides encoding polypeptides and methods using same | |
| JP2002521055A5 (enExample) | ||
| WO1998055621A1 (en) | Ntn-2 member of tnf ligand family | |
| JP2002502589A5 (enExample) | ||
| JP2002518010A5 (enExample) | ||
| EP1012292A1 (en) | Ntn-2 member of tnf ligand family | |
| NZ258697A (en) | Elk-l polypeptide, coding sequence and vector therefor | |
| CA2399593A1 (en) | Antibodies to ccr5 | |
| WO2001021631A2 (en) | Secreted proteins and uses thereof | |
| CA2343655A1 (en) | Interleukin 17-like receptor protein | |
| EP1007537A1 (en) | Receptor protein designated 2f1 | |
| EP0807177A1 (en) | A new chemokine expressed in fetal spleen, its production and uses | |
| CA2323776A1 (en) | Cytokine receptor common gamma chain like | |
| US7176180B2 (en) | Type 2 cytokine receptor and nucleic acids encoding same | |
| JP2002504333A5 (enExample) | ||
| CA2270913A1 (en) | Human tumor necrosis factor receptor-like 2 | |
| CN102030822A (zh) | 人类新细胞因子VSTM1-v2及其应用 | |
| EP0585801B1 (en) | Bone-related cadherin-like protein and process for its production | |
| WO2000069880A1 (en) | Il-9/il-2 receptor-like molecules and uses thereof | |
| US7160994B2 (en) | Osteoclast-specific genes and proteins and uses thereof | |
| JP2002522021A5 (enExample) | ||
| US7074616B1 (en) | Mouse CXC chemokine receptor |